Scrip
Erbitux not recommended for EU approval in lung cancer
24 July 2009
Malini Guha
Merck Serono (Merck KGaA)'s Erbitux (cetuximab) has been hit with a negative opinion from the EU's
CHMP, recommending against its approval in EGFR-expressing advanced non-small cell lung cancer (NSCLC), which would have been the EGFR-targeted anticancer's biggest approval to date.
Merck Serono...
Please Login to read the full article.
24 July 2009
Malini Guha
Merck Serono...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono to appeal against CHMP opinion on Erbitux in NSCLC
- Experts still see some hope for Avastin in adjuvant colon cancer
- New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancer patients
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
